These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24711709)

  • 21. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes.
    Nosadini R; Brocco E
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():1-7. PubMed ID: 9288531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.
    Krolewski AS; Gohda T; Niewczas MA
    Clin Exp Nephrol; 2014 Aug; 18(4):571-83. PubMed ID: 24218296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
    J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches to the treatment of nephropathy in diabetes.
    Thomas MC; Groop PH
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1057-71. PubMed ID: 21745151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between glucose control and the development of diabetic nephropathy in type I diabetes.
    Molitch ME
    Semin Nephrol; 1997 Mar; 17(2):101-13. PubMed ID: 9148376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is antihypertensive treatment the same for NIDDM and IDDM patients?
    Parving HH
    Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S43-7. PubMed ID: 9649959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
    Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007.
    Fioretto P; Caramori ML; Mauer M
    Diabetologia; 2008 Aug; 51(8):1347-55. PubMed ID: 18528679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of continuity of care on the incidence of end-stage renal disease in patients with newly detected type 2 diabetic nephropathy: a retrospective cohort study.
    Jang YJ; Choy YS; Nam CM; Moon KT; Park EC
    BMC Nephrol; 2018 Jun; 19(1):127. PubMed ID: 29871604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
    Parving HH
    J Hypertens Suppl; 1998 Jan; 16(1):S99-101. PubMed ID: 9534107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
    de Zeeuw D; Ramjit D; Zhang Z; Ribeiro AB; Kurokawa K; Lash JP; Chan J; Remuzzi G; Brenner BM; Shahinfar S
    Kidney Int; 2006 May; 69(9):1675-82. PubMed ID: 16572114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters.
    Al-Rubeaan K; Siddiqui K; Alghonaim M; Youssef AM; AlNaqeb D
    Ann Saudi Med; 2018; 38(1):46-56. PubMed ID: 29295969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetic nephropathy-pathophysiology and management.
    Shumway JT; Gambert SR
    Int Urol Nephrol; 2002; 34(2):257-64. PubMed ID: 12775108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus.
    Araki S; Haneda M; Koya D; Kashiwagi A; Uzu T; Kikkawa R
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S54-8. PubMed ID: 18947896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
    Wadén JM; Dahlström EH; Elonen N; Thorn LM; Wadén J; Sandholm N; Forsblom C; Groop PH;
    Diabetologia; 2019 Jul; 62(7):1268-1274. PubMed ID: 31127314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan.
    Yang WC; Hwang SJ; Chiang SS; Chen HF; Tsai ST
    Diabetes Res Clin Pract; 2001 Nov; 54 Suppl 1():S47-54. PubMed ID: 11580969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.
    Krolewski AS; Skupien J; Rossing P; Warram JH
    Kidney Int; 2017 Jun; 91(6):1300-1311. PubMed ID: 28366227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats.
    Rao RP; Singh A; Jain AK; Srinivasan BP
    J Biomed Res; 2011 Nov; 25(6):411-7. PubMed ID: 23554718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Novel biomarkers for diabetic nephropathy].
    Araki S
    Rinsho Byori; 2014 Feb; 62(2):171-9. PubMed ID: 24800493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.